The foundation of ECM Biomedical is rooted in a simple yet profound belief:
Advancing Healing with the Gift of Humanity.

We believe that the most effective medical materials originate from the most natural source—the human body itself. The human body holds an unparalleled regenerative potential, and our mission is to harness that potential through science and technology, transforming it into safe, implantable regenerative biomaterials that can be used in surgery to promote healing and restoration.

Founded in 2022, ECM Biomedical Co., Ltd. was established on the conviction that regenerative medicine should not remain a distant concept confined to the laboratory—it should be an attainable hope for every patient. Witnessing the struggles of critically ill patients, we recognized the significant unmet clinical needs in tissue repair and wound management. This realization led us to enter this highly specialized and challenging field.

As regenerative medicine continues to advance, the demand for human-derived biomaterials is rapidly growing—not only within the medical field but also in drug development, 3D organ printing, and precision medicine. The company’s name, ECM Biomedical, originates from the concept of the Extra-Cellular Matrix (ECM)—the fundamental architecture of organs and tissues.

At ECM Biomedical, we take on one of the most demanding material sources—human organs and tissues—as the foundation of our research and development. Through scientific processing and rigorous laboratory procedures, we specialize in developing human tissue–based regenerative materials, transforming them into implantable, regenerative medical products that are actively applied in diverse surgical and clinical care settings.

Driven by innovative R&D and material science expertise, ECM Biomedical focuses on enhancing therapeutic efficacy—helping patients recover tissue integrity, restore functionality, and experience a healing journey with less pain and more hope.

ECM Biomedical is more than a medical device manufacturer—it is a comprehensive solution provider, bridging clinical needs, technological breakthroughs in regenerative science, and global regulatory compliance.
Based in Taiwan as our manufacturing and R&D hub, we target the emerging Asian healthcare markets, introducing human organ- and tissue–derived regenerative products that combine scientific validity, clinical effectiveness, and market feasibility. Our ultimate goal is to bring these advanced regenerative medical solutions to the global stage.

In just three years, ECM Biomedical has achieved multiple milestones of significance:
Passing Ministry of Health and Welfare inspections, obtaining product approval for amniotic membrane, and in 2025, securing Taiwan’s exclusive approval for decellularized dermis and DBM (Demineralized Bone Matrix) products.
Today, ECM Biomedical stands as the only company in Asia possessing integrated production technologies for amniotic membrane, bone matrix, and decellularized dermis—rooted in Taiwan, advancing globally.